See more : Martello Technologies Group Inc. (DRKOF) Income Statement Analysis – Financial Results
Complete financial analysis of ZIVO Bioscience, Inc. (ZIVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ZIVO Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- C Cheng Holdings Limited (1486.HK) Income Statement Analysis – Financial Results
- Asia Holdings Co., Ltd. (002030.KS) Income Statement Analysis – Financial Results
- Rane Engine Valve Limited (RANEENGINE.BO) Income Statement Analysis – Financial Results
- Jiangsu Goodwe Power Supply Technology Co., Ltd (688390.SS) Income Statement Analysis – Financial Results
- United Hampshire US Real Estate Investment Trust (ODBU.SI) Income Statement Analysis – Financial Results
ZIVO Bioscience, Inc. (ZIVO)
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 27.65K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.89K | 82.73K | 79.14K | 176.90K | 161.34K | 297.30K | 95.97K | 49.06K | 1.68K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 16.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 138.25K | 51.81K | 63.69K | 130.04K | 167.92K | 252.88K | 191.66K | 75.28K | 1.86K | 0.00 | 0.00 | 0.00 |
Gross Profit | 11.61K | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -34.36K | 30.92K | 15.45K | 46.87K | -6.58K | 44.42K | -95.70K | -26.23K | -183.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 41.99% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33.07% | 37.37% | 19.52% | 26.49% | -4.08% | 14.94% | -99.72% | -53.46% | -10.89% | 0.00% | 0.00% | 0.00% |
Research & Development | 1.38M | 2.24M | 2.12M | 3.75M | 2.31M | 2.81M | 2.38M | 788.97K | 1.03M | 1.97M | 1.02M | 677.49K | 377.89K | 395.57K | 339.32K | 148.83K | 323.19K | 333.28K | 118.11K | 192.37K | 55.71K | 0.00 | 0.00 | 0.00 |
General & Administrative | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.59M | 2.09M | 1.40M | 1.51M | 3.60M | 2.10M | 898.90K | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.63K | 0.00 | 0.00 | 13.73K | 96.79K | 225.13K | 209.19K | 159.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 5.90M | 6.49M | 6.93M | 4.82M | 6.05M | 3.32M | 3.95M | 2.70M | 2.02M | 1.79M | 2.09M | 1.40M | 1.53M | 3.70M | 2.33M | 1.11M | 1.90M | 3.55M | 2.97M | 3.62M | 484.93K | 3.43K | 0.00 | 0.00 |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 652.50K | 0.00 | 0.00 | -582.00 | 0.00 | 15.00K | 0.00 | 0.00 | 2.06K | 3.61K |
Operating Expenses | 7.27M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 1.90M | 4.09M | 2.67M | 1.26M | 2.23M | 3.88M | 3.08M | 3.83M | 540.63K | 3.43K | 2.06K | 3.61K |
Cost & Expenses | 7.29M | 8.73M | 9.05M | 8.58M | 8.35M | 6.13M | 6.33M | 3.49M | 3.06M | 3.76M | 3.11M | 2.08M | 2.04M | 4.14M | 2.73M | 1.39M | 2.40M | 4.14M | 3.28M | 3.91M | 542.50K | 3.43K | 2.06K | 3.61K |
Interest Income | 0.00 | 13.32K | 233.28K | 550.05K | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.24K | 6.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 514.17K | 13.32K | 233.28K | 550.05K | 3.16M | 8.10M | 1.83M | 986.19K | 720.71K | 589.57K | 4.49M | 896.97K | 47.11K | 13.96K | 5.75K | 9.34K | 38.94K | 73.51K | 77.62K | 1.31K | 0.00 | -3.43K | -2.06K | -3.61K |
Depreciation & Amortization | 0.00 | 4.00 | -407.49K | 8.56M | 8.35M | 18.75K | 18.75K | 25.00K | 25.00K | 29.84K | 25.69K | 74.81K | 92.40K | 37.53K | 99.58K | 33.54K | 112.81K | 632.00K | 448.59K | 15.53K | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -7.26M | -8.73M | -9.05M | -550.05K | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.02M | -2.62M | -1.18M | -2.12M | -3.21M | -2.73M | -3.84M | -540.82K | -3.43K | -2.06K | -3.61K |
EBITDA Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -294.94% | -1,179.88% | -4,796.11% | -329.03% | -1,379.45% | -1,201.57% | -63.92% | -7,831.89% | -32,191.49% | 0.00% | 0.00% | 0.00% |
Operating Income | -7.26M | -8.73M | -9.05M | -8.56M | -8.35M | -6.13M | -6.33M | -3.49M | -3.06M | -5.15M | -3.11M | -2.08M | -1.94M | -4.06M | -2.65M | -1.21M | -2.23M | -3.84M | -3.18M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
Operating Income Ratio | -26,267.67% | 0.00% | 0.00% | -42,778.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,865.71% | -4,909.09% | -3,352.50% | -684.02% | -1,385.08% | -1,291.33% | -3,313.23% | -7,863.55% | -32,191.49% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | -514.17K | -13.32K | -110.76K | -550.05K | -3.16M | -8.50M | -3.71M | -2.57M | -2.73M | 5.83M | -6.99M | -1.17M | -793.30K | -3.05M | 1.24M | -594.44K | -16.31K | 365.15K | -2.67M | 0.00 | 540.82K | 0.00 | 0.00 | 0.00 |
Income Before Tax | -7.78M | -8.75M | -9.16M | -9.11M | -11.51M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -3.48M | -7.11M | -1.41M | -1.80M | -2.13M | -3.47M | -5.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax Ratio | -28,127.25% | 0.00% | 0.00% | -45,528.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3,347.55% | -8,592.94% | -1,783.05% | -1,020.05% | -1,320.78% | -1,168.51% | -6,095.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -4.00 | 233.28K | 550.05K | 3.16M | 407.49K | 1.66M | 1.40M | 1.83M | -5.20M | 2.50M | 270.85K | 2.29M | 6.09M | -2.48M | 1.19M | -126.38K | -736.49K | 5.37M | 1.31K | 540.82K | 3.43K | 2.06K | 3.61K |
Net Income | -7.78M | -8.75M | -9.40M | -9.66M | -14.67M | -14.64M | -10.04M | -6.06M | -5.79M | 680.81K | -10.10M | -3.25M | -2.73M | -7.12M | -1.42M | -1.81M | -2.25M | -3.54M | -5.96M | -3.86M | -540.82K | -3.43K | -2.06K | -3.61K |
Net Income Ratio | -28,127.25% | 0.00% | 0.00% | -48,278.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,629.30% | -8,609.82% | -1,790.32% | -1,025.33% | -1,395.18% | -1,191.15% | -6,207.23% | -7,866.21% | -32,191.49% | 0.00% | 0.00% | 0.00% |
EPS | -4.60 | -5.58 | -7.40 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.20 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
EPS Diluted | -4.60 | -5.57 | -7.39 | -11.41 | -25.47 | -44.84 | -34.60 | -21.73 | -21.22 | 1.79 | -43.19 | -15.38 | -2.26 | -6.54 | -1.54 | -2.77 | -4.25 | -8.26 | -26.13 | -27.12 | -4.49 | -0.18 | -0.22 | -0.39 |
Weighted Avg Shares Out | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.70K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
Weighted Avg Shares Out (Dil) | 1.69M | 1.57M | 1.27M | 846.21K | 575.83K | 326.41K | 290.09K | 278.84K | 272.80K | 379.59K | 233.78K | 211.25K | 1.21M | 1.09M | 920.65K | 655.39K | 529.93K | 428.93K | 227.95K | 142.31K | 120.34K | 18.56K | 9.28K | 9.28K |
ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study
ZIVO Bioscience Announces Uplisting to OTCQB Market
ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Bioscience Announces Reverse Stock Split
ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference
Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months
ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food
ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News
Source: https://incomestatements.info
Category: Stock Reports